The same genetic variant found in different individuals can cause a range of diverse
phenotypes, from no discernible clinical phenotype to severe disease, even among related …

Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary
hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure …

Background Mutations in the gene encoding the bone morphogenetic protein receptor type II
(BMPR2) are the commonest genetic cause of pulmonary arterial hypertension (PAH) …

Some individuals with a particular disease-causing mutation or genotype fail to express
most if not all features of the disease in question, a phenomenon that is known as 'reduced …

Pulmonary arterial hypertension (PAH), the first category of pulmonary hypertension, is a
chronic and progressive disorder characterised by angioproliferative vasculopathy in the …

Pulmonary arterial hypertension (PAH) is an often fatal disorder resulting from several
causes including heterogeneous genetic defects. While mutations in the bone …

Balanced transforming growth factor-beta (TGFβ)/bone morphogenetic protein (BMP)-
signaling is essential for tissue formation and homeostasis. While gain in TGFβ signaling is …

Pulmonary arterial hypertension (PAH) is a disorder in which mechanical obstruction of the
pulmonary vascular bed is largely responsible for the rise in mean pulmonary arterial …

Pulmonary arterial hypertension (PAH) is a progressive and fatal disease for which there is
an ever-expanding body of genetic and related pathophysiological information on disease …

The last 2 generations of physicians and researchers in pulmonary hypertension (PH) have
undergone their training, performed investigations, and practiced without a thorough …